HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm.

AbstractBACKGROUND:
Azimilide dihydrochloride (azimilide) is an investigational antiarrhythmic drug that has been tested in patients with a variety of arrhythmias. In patients with atrial fibrillation, it has shown excellent efficacy in some previous trials and minimal efficacy in others.
METHODS:
Patients who had symptomatic atrial fibrillation for > 48 hours but < 6 months were eligible for this multicenter, randomized, placebo-controlled clinical trial. Patients were admitted to a hospital and randomly assigned to receive either azimilide 125 mg or a matched placebo twice daily for 3 days and then once daily. Patients who were in sinus rhythm spontaneously or had sinus rhythm restored by electric cardioversion on day 4 were discharged from the hospital. Recurrence of atrial fibrillation was documented by electrocardiogram. In the primary efficacy analysis, time to recurrence in the 2 treatment groups was compared with the log-rank test in the subgroup of patients with structural heart disease. Safety was assessed as deaths, adverse events, and serious adverse events.
RESULTS:
A total of 446 patients were randomized in the study; 314 were in the subgroup with structural heart disease. The median time to arrhythmia recurrence in both treatment groups with structural heart disease was 13 days, and the difference between treatments was not significant (P = .4596, n = 314). The relative risk for recurrence (placebo:azimilide) was 1.104 (95% CI 0.849-1.436). There was 1 death in the placebo group and 3 in the azimilide group.
CONCLUSIONS:
Azimilide did not demonstrate clinically important or statistically significant efficacy in reducing the risk for arrhythmia recurrence in patients with structural heart disease who were in atrial fibrillation and converted to sinus rhythm.
AuthorsEdward L C Pritchett, Peter Kowey, Stuart Connolly, Richard L Page, Charles Kerr, William E Wilkinson, A-COMET-I Investigators
JournalAmerican heart journal (Am Heart J) Vol. 151 Issue 5 Pg. 1043-9 (May 2006) ISSN: 1097-6744 [Electronic] United States
PMID16644334 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
Chemical References
  • Anti-Arrhythmia Agents
  • Hydantoins
  • Imidazolidines
  • Piperazines
  • azimilide
Topics
  • Aged
  • Anti-Arrhythmia Agents (adverse effects, therapeutic use)
  • Arrhythmias, Cardiac (mortality)
  • Atrial Fibrillation (drug therapy, physiopathology)
  • Female
  • Heart Rate (drug effects)
  • Humans
  • Hydantoins
  • Imidazolidines (adverse effects, therapeutic use)
  • Long QT Syndrome (chemically induced)
  • Male
  • Middle Aged
  • Piperazines (adverse effects, therapeutic use)
  • Syncope (chemically induced)
  • Torsades de Pointes (chemically induced)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: